Clinical Trial Update: ²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma [Phase 1]

View source ↗

Summary

Phase 1 study evaluating 211At-OKT10-B10 with fludarabine, with or without cyclophosphamide and low-dose total body irradiation, as conditioning before donor st…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• 211At-OKT10-B10
• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Fludarabine (Fludarabine)

Snippet

Sponsor: Fred Hutchinson Cancer Center | Conditions: Multiple Myeloma, Recurrent Multiple Myeloma | Phase 1 | Status: NOT_YET_RECRUITING